Search

Author/Creator Friedman, A.

1. A Novel Algorithm for the Assessment of Blood-Brain Barrier Permeability Suggests That Brain Topical Application of Endothelin-1 Does Not Cause Early Opening of the Barrier in Rats. (27th February 2011)

Authors:
Jorks, D.; Milakara, D.; Alam, M.; Kang, E. J.; Major, S.; Friedman, A.; Dreier, J. P.
Other Names:
Kaufer Daniela Academic Editor.
Journal:
Cardiovascular psychiatry and neurology
Issue:
Volume 2011(2011)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0·5 mg kg−1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. (1st July 2015)

Authors:
Chalmers, J.R.; Wojnarowska, F.; Kirtschig, G.; Nunn, A.J.; Bratton, D.J.; Mason, J.; Foster, K.A.; Whitham, D.; Williams, H.C.; Williams, H.; Mason, J.; McDermott, M.; Yong, A.; Chriba, M.; Banks‐Dunnell, K.; Butcher, D.; Cox, N.; Nik, M.; Gilbanks, K.; Davies, K.
Journal:
British journal of dermatology
Issue:
Volume 173:Number 1(2015:Jul.)
Page Start:
227
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0·5 mg kg−1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. (26th May 2015)

Authors:
Chalmers, J.R.; Wojnarowska, F.; Kirtschig, G.; Nunn, A.J.; Bratton, D.J.; Mason, J.; Foster, K.A.; Whitham, D.; Williams, H.C.; the BLISTER study group; Williams, H.; Mason, J.; McDermott, M.; Yong, A.; Chriba, M.; Banks‐Dunnell, K.; Butcher, D.; Cox, N.; Nik, M.; Gilbanks, K.
Journal:
British journal of dermatology
Issue:
Volume 173:Number 1(2015:Jul.)
Page Start:
227
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. AB0390 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance To Anti-TNF Biologic Therapy. (15th July 2016)

Authors:
Kremer, J.M.; Keystone, E.C.; Emery, P.; Camp, H.S.; Friedman, A.; Wang, L.; Othman, A.A.; Khan, N.; Jungerwirth, S.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75(2016)Supplement 2
Page Start:
1038
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson's disease and other neurologic conditions. (October 2020)

Authors:
Pagan, F.; Jost, W.H.; Friedman, A.; Michel, O.; Oehlwein, C.; Slawek, J.; Bogucki, A.; Ochudlo, S.; Banach, M.; Flatau-Baqué, B.; Csikós, J.; Blitzer, A.
Journal:
Parkinsonism & related disorders
Issue:
Volume 79(2020) Supplement 1
Page Start:
e85
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗